The reaffirmed full-year guidance suggests management sees no material change in business momentum. Monitor the Q4 2026 earnings for any revision to the 2027 outlook, particularly given the Nordion segment's harvest-timing volatility and the impact of foreign currency headwinds (revised to 70 bps from 100 bps).
Price Chart
Executive Summary
Sotera Health reported Q3 2026 net revenues of $324.9M, up 4.4% YoY, and Adjusted EPS of $0.29, a 12% increase. The company reaffirmed its full-year 2026 constant currency revenue and Adjusted EBITDA growth outlook of 5.25%-6.75% and 5.75%-7.25% respectively, while narrowing interest expense guidance. Results were solid but in line with the reaffirmed outlook, with no change to the full-year guidance range.
Key Financial Metrics
Key Facts
- Q3 2026 net revenues of $324.9M, up 4.4% YoY on both as-reported and constant currency basis
- Q3 2026 GAAP net income of $58.4M or $0.20 per diluted share, vs $48.4M or $0.17 in Q3 2025
- Q3 2026 Adjusted EPS of $0.29, up 12% YoY from $0.26
- Q3 2026 Adjusted EBITDA of $170.7M, up 3.9% (4.0% constant currency)
- Full-year 2026 outlook reaffirmed: net revenues $1.233B-$1.250B, Adjusted EBITDA $632M-$641M, both on constant currency growth of 5.25%-6.75% and 5.75%-7.25% respectively
- Net leverage ratio improved to 2.9x as of September 30, 2026, within the 2.0x-3.0x target range
- Credit rating upgrade from Moody's Ratings in early October
- Nordion segment revenue declined 12.4% (11.5% constant currency) due to expected Cobalt-60 harvest timing
Financial Impact
Q3 2026 net revenues $324.9M, Adjusted EBITDA $170.7M, Adjusted EPS $0.29; full-year guidance unchanged
Segment Breakdown
| Segment | Revenue | Growth |
|---|---|---|
| Sterigenics | $209.3M | +8.5% |
| Nordion | $55.0M | -12.4% |
| Nelson Labs | $60.6M | +8.8% |
Risk Factors
- Nordion segment revenue decline due to Cobalt-60 harvest timing
- Foreign currency headwind revised to 70 bps from 100 bps, reducing the benefit to revenue and EBITDA
- Ongoing ethylene oxide (EO) litigation costs and professional fees
- Inflationary pressures on costs and supply chain
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001822479-26-000055 |
| Document: shc-20261103.htm | 0001822479-26-000055 |
| Document: 0001822479-26-000055-index-headers.html | 0001822479-26-000055 |
| Document: 0001822479-26-000055-index.html | 0001822479-26-000055 |
| Document: 0001822479-26-000055.txt | 0001822479-26-000055 |
| 8-K Data (Synthetic) | 0001822479-26-000055 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Nov 3, 2026 3d ago | 8-K | No price | awaiting T+1 | awaiting T+1 | No price |
Nov 3, 2026 3d ago | Press Release | $16.03 $16.39 | ▲ +2.25% | ▲ +0.59% | $15.94 (−0.56%) |
Oct 30, 2026 7d ago | SC 13G | $18.15 $17.74 | ▼ −2.26% | ▼ −1.78% | $15.94 (−12.18%) |
Oct 21, 2026 15d ago | Institutional Cluster | $18.13 $18.10 | ▼ −0.17% | ▲ +0.36% | $15.94 (−12.08%) |
Oct 9, 2026 27d ago | SC 13G/A | $18.15 $18.21 | ▼ −0.33% | ▼ −0.34% | $15.94 (+12.18%) |
Aug 14, 2026 12w ago | 8-K | $18.89 $18.80 | ▼ −0.48% | ▼ −0.00% | $15.94 (−15.62%) |
Aug 9, 2026 12w ago | Institutional Cluster | $18.97 $19.11 | ▲ +0.74% | ▲ +1.06% | $15.94 (−15.97%) |
Aug 7, 2026 13w ago | 144 | $18.86 $18.97 | ▲ +0.58% | ▲ +0.61% | $15.94 (−15.48%) |
Aug 6, 2026 13w ago | 8-K | $18.91 $18.86 | ▼ −0.26% | ▼ −0.88% | $15.94 (−15.71%) |
May 27, 2026 23w ago | 3 | $15.75 $15.64 | ▼ −0.70% | ▼ −0.94% | $15.94 (+1.21%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers